香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 榮昌生物製藥（煙台）股份有限公司 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 董事長兼執行董事 王威東先生 中國煙台 2025年8月22日 （股份代號：9995） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由榮昌生物製藥 （煙台）股份有限公司（「本公司」）作出。 茲載列本公司於上海證券交易所網站刊登公告如下，僅供參閱。 承董事會命 於本公告日期，董事會成員包括執行董事王威東先生、房健民博士、林健先生及 溫慶凱先生；非執行董事王荔強博士及蘇曉迪博士；及獨立非執行董事郝先經先 生、陳雲金先生及黃國濱先生。 * 僅供識別 荣昌生物制药（烟台）股份有限公司 2025 年半年度报告摘要 公司代码：688331 公司简称：荣昌生物 荣昌生物制药（烟台）股份有限公司 2025 年半年度报告摘要 ...

Core Viewpoint - Nanjing Weilizhibo Biotechnology Co., Ltd. is embarking on its journey to list on the Hong Kong Stock Exchange, focusing on innovative therapies for cancer and autoimmune diseases, with a pipeline of 12 drug candidates, 6 of which are in clinical stages [1][3]. Financial Performance - In 2023, the company reported revenue of 8.87 million RMB, with no new revenue recorded thereafter. The losses for 2023 and 2024 were 360 million RMB and 301 million RMB, respectively, with R&D expenditures of 231 million RMB and 186 million RMB [1][2]. - Administrative expenses increased from 38 million RMB to 87.69 million RMB from 2023 to 2024. In Q1 2025, R&D spending was 57.75 million RMB, with a loss of 75.37 million RMB, showing a reduction compared to the same period last year [2][3]. Cash Position and Funding - As of March 31, 2025, the company held cash and cash equivalents of 431 million RMB, providing support for ongoing R&D and market expansion [3]. - Since its inception, Weilizhibo has raised over 1 billion RMB through multiple funding rounds, including a significant 607 million RMB in its C round in 2021, and has established partnerships that may yield substantial returns [3]. Shareholding Structure - The company's executive directors, including Dr. Kang Xiaoqiang and Dr. Lai Shoupeng, collectively control approximately 20.08% of the voting rights through a concerted action agreement. Major shareholders include well-known investment firms such as Enran Venture Capital and Zhengxin Valley Capital [3][5].